Patents
Literature
61 results about "Basal ganglia dysfunction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Damage to the basal ganglia cells may cause problems controlling speech, movement, and posture. This combination of symptoms is called parkinsonism. A person with basal ganglia dysfunction may have difficulty starting, stopping, or sustaining movement.
Quinolinone PDE2 inhibitors
The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Quinolinone PDE2 Inhibitors
The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Aryl aminopyridine pde10 inhibitors
The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME CORP
Isoindoline pde10 inhibitors
The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME CORP
Pyrazolopyrimidine PDE 10 inhibitors
The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Cyclobutyl benzimidazoles as PDE 10 inhibitors
ActiveUS20150307479A1Useful in therapyBiocideOrganic active ingredientsBasal ganglia dysfunctionPhosphodiesterase
The present invention is directed to substituted cyclobutyl benzimidazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME CORP
Alkoxy pyrimidine PDE10 inhibitors
The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors
The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Triazolyl pyrimidinone compounds as PDE2 inhibitors
InactiveCN107530343AOrganic active ingredientsNervous disorderBasal ganglia dysfunctionHuntingtons chorea
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK & CO INC
Secondary alcohol substituted triazoles as pde10 inhibitors
The present invention is directed to secondary alcohol substituted triazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
1,3 substituted azetidine pde10 inhibitors
The present invention is directed to substituted azetidinecompounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
The present invention is directed to amino tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME CORP
Bicyclic heterocyclic compounds as PDE2 inhibitors
The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Pyrazolopyrimidine pde9 inhibitors
ActiveUS20180354955A1Useful in therapyOrganic active ingredientsNervous disorderHuntingtons choreaPhosphodiesterase
The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Substituted pyridone derivatives as PDE10 inhibitors
The present invention is directed to substituted pyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC +1
Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Substituted pyridone derivatives as PDE10 inhibitors
The present invention is directed to substituted pyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Phenyl-cyanoquinolinone PDE9 inhibitors
The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Aza-cyanoquinolinone pde9 inhibitors
The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors
The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds of formula I, which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME CORP
Triazolopyridinone pde10 inhibitors
The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC +1
Aryl aminopyridine PDE10 inhibitors
Owner:MERCK SHARP & DOHME CORP
Pyrazolopyrimidine PDE 10 inhibitors
The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors
ActiveUS20180280390A1Organic active ingredientsNervous disorderHuntingtons choreaBasal ganglia dysfunction
The present invention is directed to substituted pyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Pyrimidine PDE10 inhibitors
ActiveUS9062059B2Organic active ingredientsNervous disorderBasal ganglia dysfunctionPhosphodiesterase
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Owner:MERCK SHARP & DOHME LLC
Substituted amino-triazolyl pde10 inhibitors
Owner:MERCK SHARP & DOHME CORP
Lower limb dyskinesia adjusting equipment and gait adjusting method
The invention discloses lower limb dyskinesia adjusting equipment and a gait adjusting method, and the equipment comprises a wearing part which comprises a housing matched with a lower limb; the projection module comprises a projector arranged on the shell, and the projection angle of the projector is adjustable; the control unit comprises a control mainboard arranged in the shell and an acquisition module communicating with the control mainboard, and the acquisition module is configured to acquire gait data of the wearing piece in real time; the projector communicates with the control mainboard, and the control mainboard is configured to control and adjust the projection angle of the projector based on the gait data acquired by the acquisition module. The lower limb dyskinesia adjusting device prompts gait disorders by using vision, and the mechanism is that the lower limb dyskinesia adjusting device can provide external sensory cues for the patient and stimulate the visual system of the patient, so that neural activity of the premotor area is activated. Visual information is used for guiding gaits, and the deficiency of internal movement rhythm caused by basal ganglion dysfunction is made up.
Owner:FITZMAN HEALTH TECHNOLOGY (TIANJIN) CO LTD